SOURCE: BioTech Medics, Inc.

June 04, 2007 09:35 ET

BioTech Medics, Inc. Hits Two-Year High

DALLAS, TX--(Marketwire - June 4, 2007) - BioTech Medics, Inc. (PINKSHEETS: BTME) (formerly: BTMD) hit a two-year high on June 1 of $.10 per common share. BioTech announced on June 1 a reverse stock split and a symbol change.

The new BTME high also exceeded a short sale squeeze trigger price above $.02 which was previously ascertained and reported by the Company from

According to the OTCBB Short Positions Report it appears that the Company stock has not been shorted heavily. However, in discussing the matter with an official of OTCBB the Company ascertained several flaws in the reporting requirements. The first is that there are no assurances that all NASD member firms are 100% compliant in reporting. Secondly, offshore, non-NASD member firms are not subject to the reporting. Therefore, an offshore firm could heavily short a stock with millions of shares. Lastly, those who desire to short a stock and remain anonymous can short a stock all month except on the 15th of each month, the reporting day, thus legally circumventing reporting.

BTME is alternative medicine for the twenty-first century. BioTech Medics is a high-powered therapeutic medical laser manufacturer and distributor of Class IIIB-FDA cleared non-hazardous lasers which are for the reduction and/or elimination of acute and chronic muscular, skeletal and/or arthritic pain.

Conditions such as arthritis pain, carpal tunnel, joint pain, nerve pain from sports injuries, accidents, work related injuries or just aging can be treated easily and non-surgically in one of BioTech's Pain Management & Well Centers.

BioTech is the patent holder of SHBAN™ Hand Sanitizer which is an antimicrobial clinically proven to kill the Avian Bird Flu Virus together with most common germs, and bacteria. SHBAN is superior to other hand sanitizers because SHBAN is non-alcoholic, non-toxic (when used as directed) and leaves an invisible protective film on your hands for long-lasting protection. Additional SHBAN products are in development at this time.

Safe Harbor for Forward-Looking Statements.

This press contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 (the "Act"). Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. The FDA has made no evaluation of SHBAN. SHBAN is not made to diagnose, cure or treat any disease.

Contact Information

  • Contact:
    Investor Relations